Cassava Sciences CEO Remi Barbier resigns amid fraud charges; Richard Barry appointed Executive Chairman and principal executive officer.

Cassava Sciences, an Alzheimer's disease treatment developer, experiences leadership changes as CEO Remi Barbier resigns, with Richard Barry appointed as Executive Chairman and principal executive officer. The company is searching for a new permanent CEO, while Remi Barbier remains employed until 2024. The shake-up follows a Maryland grand jury indictment involving fraud charges related to the company's Alzheimer's drug. Shares dropped by about 35%.

Articles

Yahoo Finance

Benzinga

Biztoc

RTTNews

Seeking Alpha

Biztoc

-- show less --

Further Reading

Related Stories